Skip to main content
Article thumbnail
Location of Repository

Identification of surrogate markers for determining drug activity using proteomics

By C.M. McClelland and William J. Gullick

Abstract

In a high proportion of human carcinomas overexpression of the EGFR (epidermal growth factor receptor), a receptor tyrosine kinase, represents a potential target for cancer treatment. EGFR is induced to dimerize through ligand binding which activates the tyrosine kinase activity of the receptor. This catalyses the transfer of ATP's gamma-phosphate to hydroxyl groups of tyrosine residues on the receptor, creating binding sites that recruit downstream signalling proteins. New drugs, SMTKIs (small-molecule tyrosine kinase inhibitors), have been designed to inhibit the tyrosine kinase activity of the receptor, producing an anti-tumour effect. The development of surrogate markers to determine the drug activity of these new inhibitors would be of great benefit in drug evaluation and in the subsequent management of patient disease. This review describes current treatments of cancer using tyrosine kinase inhibitors and the use of proteomic analysis to identify possible markers of activity of these new drugs

Topics: Q, RC0254
Publisher: Portland Press
Year: 2003
OAI identifier: oai:kar.kent.ac.uk:3980
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://kar.kent.ac.uk/3980/1/B... (external link)
  • http://www.ncbi.nlm.nih.gov/en... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.